Nkarta (NKTX) Net Margin (2019)
Nkarta (NKTX) posted quarterly Net Margin of 1638637.4% for Q3 2019, up 879.95% quarter-over-quarter from 210093.89% in Q2 2019.
Nkarta (NKTX) Net Margin (2019) Analysis & Trends
Nkarta's Net Margin history runs 1 years deep, the most recent figure standing at 1638637.4% for Q3 2019.
- In Q3 2019, Net Margin changed N/A year-over-year to 1638637.4%; the TTM figure through Dec 2020 stood at 13714285.71% (changed N/A YoY), while the FY2019 annual figure was 20461.74%, changed N/A from the prior year.
- Net Margin for Q3 2019 stood at 1638637.4%, up from 210093.89% in the prior quarter.
- The five-year high for Net Margin was 1638637.4% in Q3 2019, with the low at 210093.89% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Nkarta | 185.49 Mn | 185.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 1,638,637.40% |
| Jun 30, 2019 | -210,093.89% |